

# TECHNICAL EXPERT PANEL (TEP) NOMINATION FORM

**Project Title:** Development, Reevaluation, and Implementation of Outcome and Efficiency Measures

**Project Overview:**

The Centers for Medicare & Medicaid Services (CMS) has contracted with Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation (CORE), and its partner the Lewin Group (Lewin), to develop an electronic clinical quality measure (eCQM) that assesses the percentage of patients that received fibrinolytic therapy within 30 minutes of emergency department (ED) arrival. The contract name is Development, Reevaluation, and Implementation of Outcome and Efficiency Measures. The contract number is HHSM-500-2013-13018I. As part of its measure development process, CMS asks measure developers to convene groups of stakeholders and experts who contribute direction and thoughtful input to the measure developer during measure development and maintenance.

Per the MMS Blueprint for the CMS Measures Management System, eCQMs are based on information readily available in electronic health records (EHR) in a structured format and can be readily accessed without affecting facility workflow. The electronic specification of the measure will ensure that all data elements used to calculate the measure's performance score can be captured in the EHR.

**Project Objectives:**

The project's primary objective is to convert OP-2 (Fibrinolytic Therapy Received within 30 Minutes of ED Arrival) to an eCQM, including its electronic specification, and testing of feasibility, validity, and effectiveness, recommending improvements as needed.

**TEP Expected Time Commitment:**

Members of the TEP will meet up to three times per year via teleconference. Typical TEP teleconference meetings last between one and two hours. This project is anticipated to continue through September 2018. Additional time will be required to read meeting materials ahead of each meeting and TEP members may be called upon periodically to review information and provide comments between meetings.

**TEP Requirements:**

We are seeking a TEP of approximately 12 to 15 individuals who will recommend feedback and provide perspectives on the conversion of OP-2 (Fibrinolytic Therapy Received within 30 Minutes of EDT Arrival) to an eCQM. The TEP will be composed of individuals with the following areas of expertise and perspectives:

EHR vendors

Policy makers

Clinicians or other caregivers with subject matter expertise, including cardiology, emergency medicine, and rural and critical access communities

Guideline developers

Informaticists, epidemiologists, methodologists, and other experts in measurement science

Quality measure experts

Patients and caregivers

Consumer advocates

Health system and hospital representatives

Disparities experts

Payers and Healthcare purchasers

**Instructions:**

Applicants/nominees must submit the following documents ***with this completed and signed form***:

A letter of interest (not to exceed two pages) highlighting experience/knowledge relevant to the expertise described above and involvement in measure development.

*Curriculum vitae* or a summary of relevant experience (including publications) for a maximum of 10 pages. (Patient participants may elect to keep their names confidential in public documents.)

The 30-day TEP nomination period opens on September 05, 2017 and closes on October 13, 2017.

***Please send this completed and signed TEP Nomination form, statement of interest, CV*** to Claire Russell of the Lewin Group with “Nomination” in the subject line at [Claire.Russell@lewin.com](mailto:Claire.Russell@lewin.com). Due by close of business October 13, 2017 (Eastern Time).

Potential TEP members must be aware that participation on the TEP is voluntary. As such, individuals wishing to participate on the TEP should understand that their input will be recorded in the meeting minutes. Proceedings of the TEP will be summarized in a report that is disclosed to the general public. If a participant has disclosed private, personal data by his or her own choice, then that material and those communications are not deemed to be covered by patient-provider confidentiality. If potential patient participants wish to keep their names confidential, that request can be accommodated. Any questions about confidentiality will be answered by Lewin.

All potential TEP members must disclose any significant financial interest or other relationships that may influence their perceptions or judgment. It is unethical to conceal (or fail to disclose) conflicts of interest. However, the disclosure requirement is not intended to prevent individuals with particular perspectives or strong points of view from serving on the TEP. The intent of full disclosure is to inform the measure developer, other TEP members, and CMS about the source of TEP members’ perspectives and how that might affect discussions or recommendations.

**Applicant/Nominee Information (Self-Nominations Are Acceptable):**

Name: Credentials: Professional Role:

Organizational Affiliation: City:

State:

Mailing address: Telephone: Email:

Person Recommending the Nominee:

Complete this section only if you are nominating a third party for the TEP. You must sign this form

and attest that you have notified the nominee of this action and that they are agreeable to serving on the TEP. The measure developer will request the required information from the nominee.

Name: Credentials: Professional Role:

Organizational Affiliation: City:

State:

Mailing address: Telephone: Email:

I attest that I have notified the nominee of this action and that the nominee is agreeable to serve on the TEP.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Applicant/Nominee's Disclosure:**

This section addresses disclosure of any current and past activities that may indicate a conflict of interest. As a measure developer for the Centers for Medicare & Medicaid Services (CMS), CORE and Lewin must ensure independence, objectivity, scientific rigor, and balance in its measure development activities.

Do you or any family members have a financial interest, arrangement, or affiliation with any corporate organizations that may create a potential conflict of interest? ☐ Yes ☐ No

If yes, please describe (grant/research support, consultant, speaker's bureau, and major stock shareholder, other financial or material support). Please include the name of the corporation/organization.

Do you or any family members have intellectual interest in a study or other research related to the quality measures under consideration? ☐ Yes ☐ No

If yes, please describe the type of intellectual interest and the name of the organization/group.

**Applicant/Nominee's Agreement:**

If at any time during my service as a member of this TEP my conflict of interest status changes, I will notify the measure developer and the TEP chair.

It is anticipated that there will be three meetings per 12-month period via teleconference. I am able to commit to attending the TEP meetings in person, by teleconference, or by mutually agreed-upon alternative means.

If selected to participate in the TEP and the measures are submitted to a measure endorsement organization (such as the NQF), I will be available to discuss the measures with the organization or its representatives and work with the measure developer to make revisions to the measures, if necessary.

I understand that my participation on the TEP is voluntary. As such, I understand that my input will be recorded in the meeting minutes. Proceedings of the TEP will be summarized in a report that is disclosed to the general public. If I have disclosed private, personal data by my own choice, then that material and those communications are not deemed to be subject to any confidentiality laws.

If selected to participate in the TEP, I will keep all materials and discussions confidential until such

time that CMS authorizes their release.

I have read the above and agree to abide by it.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

**For patient participants only:** I wish to keep my name confidential.

☐ Yes ☐ No